Interaction between baseline HBV loads and the prognosis of
patients with HCC who receive anti-PD-1 in combination with anantiangiogenic therapy and
are simultaneously given TAF prophylaxis
Xiaoyun Hu1*, Rong Li1*, Qi
Li1, Mengya Zang1, Guosheng
Yuan1#, Jinzhang Chen1#
Short Running title: Interaction between HBV and anti-PD-1 plus
antiangiogenic therapy
Keywords : Hepatocellular carcinoma (HCC); hepatitis B virus
(HBV); programmed cell death-1 (PD-1)/programmed cell death-ligand 1
(PD-L1); reactivation; tenofovir alafenamide fumarate (TAF)
1Department of Infectious Diseases and Hepatology
Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China
#Correspondence authors: Guosheng Yuan, PhD;
Jinzhang Chen, MD. Department of Infectious Diseases and Hepatology
Unit, Nanfang Hospital, Southern Medical University, 1,838 North
Guangzhou Ave, Guangzhou, Guangdong 510515, China. Email:
guoshengyuan1991@163.com; chenjinzhang@smu.edu.cn.